Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Pharmaceuticals Inc.

http://www.alnylam.com

Latest From Alnylam Pharmaceuticals Inc.

Advanced Therapies From Orchard & Kite Win EMA Thumbs Up

Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.

Europe Approvals

Sobi’s Doptelet Disappoints In Large New Indication

A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations. 

Clinical Trials Companies

EMA: Moment Of Truth For Two Curative Therapies & A Possible Cholesterol-Lowering Blockbuster

The sponsors of 11 new treatments should learn this week whether the European Medicines Agency will recommend EU marketing approval for their products.

Europe Approvals

‘We’re On The Edge Of Knowledge,’ Says Dewpoint CEO

Biomolecular condensates were first observed over 100 years ago, but their function – and the role they might play in a broad range of diseases – is only now being rigorously explored by drug developers. New technological development is helping scientists recreate condensates in laboratory conditions, providing insight into fundamental cellular processes. Amir Nashat, CEO of Dewpoint Therapeutics, told In Vivo that the company, following a recent $77m series B round, now has the resources to get to proof of concept for drugs targeting biomolecular condensates.

Innovation Platform Technologies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Regulus Therapeutics, Inc.
    • Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG
UsernamePublicRestriction

Register